Medication usage and Patient Reported Outcomes evaluation via myBETAapp in patients with multiple sclerosis treated with Betaferon: a pilot study (PROmyBETAapp)
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness tracker in the myBETAapp will be observed for 3 months.
-Patients aged ≥ 18 years. -Patients on treatment with Betaferon (every Betaferon box contains a “Mixject” number, which is a product specific number unrelated to the study. Only patients prescribed Betaferon for their MS will be able to use the myBETAapp and participate in the study). -Patients must be using the myBETAapp. -Electronic informed consent must be obtained.
-There are no exclusion criteria for participation in this study.
Many locations, Germany
E-mail: [email protected]
Phone: (+) 1-888-8422937
PROmyBETAapp: Ascertaining medication usage & documentation of Patient Reported Outcomes utilizing the myBETAapp® in patients with multiple sclerosis treated with Betaferon®: a pilot study